Useful contact

– For recruitment and internship files: rhcom.u1149@inserm.fr

– For your orders: orders.u1149@inserm.fr

– To request a computer intervention: info.u1149@inserm.fr

– For missions: missions.u1149@inserm.fr

– For Health and Safety questions: hs.u1149@inserm.fr

– For the set-up and questions relating to a Research project: projects.u1149@inserm.fr

– To report a problem with the website: com.u1149@inserm.fr 

– Website editorial committee: To propose news, events and publications to add to the website: webedition.u1149@inserm.fr


 
Valerie Paradis et Alain Couvineau

From inflammation to cancer in digestive diseases (INDiD)

Team Paradis / Couvineau

Department Hepato-Gastroenterology Department

 

Leader

 

Line-up

 

Presentation

This project results of the merging of 3 research teams from the past 5-years contract and aims to investigate specific aspects of the physiopathology of the sequence inflammation-cancer in digestive tract, identify new diagnostic markers and develop innovative therapeutic targets. First axis, focusing on liver carcinogenesis related to metabolic syndrome, will identify the specific mechanisms involved in inflammatory liver damages by favoring original in situ molecular approaches such as mass spectrometry imaging (MSI). The contribution of lipid environment (liver or visceral adipose tissue) in the progression to hepatocellular carcinoma (HCC) will also be investigated. Second axis will provide new insights in the role of GPCR in the progression of digestive cancers, which will allow the development of new therapeutic strategies. We will focus on (1) orexins and their receptors (OXR) which induce a robust apoptosis in digestive cancers, and (2) CXCR4 which confers survival, invasion potential to cancer cells. We will be especially interested to evaluate potential effects of these targets in preclinical models of digestive cancers that have developed resistance to conventional cytotoxic or targeted therapies.

Research projects:

Work package: Inflammation, fibrosis and cancer in the liver

Metabolic syndrome (MS) is becoming the leading cause of chronic liver diseases worldwide and may result in the development of chronic liver diseases and hepatocellular carcinoma (HCC). Progression of liver carcinogenicity in MS is complex, involving the development of tissue damages (steatosis and fibrosis) and also an inflammatory systemic background through adipokines production from visceral adipose tissue

Our project aims:

  1. To study the molecular mechanisms involved in the development of early liver damage related to MS (steatosis and steatohepatitis) which start in centrolobular area. The liver lipidomic pattern will be determined by an in situ approach. This study will allow to identify profibrogenic mediators specifically induced in the liver damage progression observed in MS. The functional role of fibrogenesis will estimated by using cell co-culture models (liver stellar cells/hepatocytes/endothelial cells).
  2. To decipher the specific molecular mechanisms involved in tumor progression associated to MS by the determination of the role of visceral adipose tissue (VAT) through the production of Fatty Acid Binging Proteins (FABPs) and lipid chaperones which are involved in the fatty acid trafficking. The role of pro-oncogenic of FABP4 will determined using in vitro and in vivo experimental models. Moreover, we will examine the impact of tissue modifications in the peritumoral hepatic parenchyma on HCC development by using in situ proteomic and lipidomic approaches. In this context, we will evaluate the anti-tumoral effects of putative therapeutical targets including the metformine.

This project will be based on the development of innovative technologies including mass spectrometry imaging (MALDI imaging), tissue culture models (ex vivo models) and animal models which reproduced liver damages related to MS (High fat diet, fructose diet …). The determination of molecular species identified by MALDI was carried out in collaboration with JM Camadro’s group (Institut J. Monod, Paris).

Work package: GPCRs and digestive cancers (Couvineau Alain’s group)

Since few years ago, drugs targeting G protein-coupled receptors GPCRs are shown to have excellent therapeutic benefits. In this context, our project is to study the role and clinical interest of GPCRs in particular orexin receptors (OXR), in digestive cancer development. Orexins, hypothalamic peptides, interacted with two GPCR (OX1R and OX2R). They regulate sleep, wakefulness, feeding, breathing, reward system, or drug addiction. We have shown that orexins induced a robust apoptosis in colon cancer cell lines which expressed OX1R. This cell death was mediated through ITIM sequence resulting in the recruitment and theactivation of the SHP-2, leading to a mitochondrial apoptosis. Furthermore, we have demonstrated that OX1R is aberrantly expressed in digestive cancers including colon cancers, pancreas cancers and liver cancers but inversely is not present in normal tissue. Moreover we have demonstrated that orexins have strong anti-tumoral effects in pre-clinical models of digestive cancers.

Our project aims:

  • To study the presence of of orexins and theirreceptors in various pre-cancerous and inflammatory states in the digestive tract, especially in the early stage of colonic and pancreatic carcinogenesis encompassing IBD and adenomas (polyps, PanIN). To evaluate the dynamic role of OX1R during the carcinogenesis, we will use various mouse models such as chemically colitis- induced mice (DSS) and/or genetically modified mice as EXCY2 model (E. Ogier-Denis, Paris) or IL10-/- (A. Jarry, Nantes) which develop spontaneously colitis-associated cancer. Xenografted models produced from patient resected tumors (xenograft derived patient, PDX) are currently in progress OX1R expression in pancreatic adenocarcinoma
  • To study the role of orexins on isolated cells and/or tumors explants maintained in culture from resected patient tumors (colon, pancreas and liver). This innovative approach developed in our team, will allow us to determine the anti-tumoral effect of orexins ex vivo by measuring various markers of apoptosis, hypoxia and angiogenesis.
  • To study the OX1R signaling pathways in which the recruitment of SHP2 and oxidative stress activation (p38, ROS, NRF2….) induces a mitochondrial apoptosis leading to anti-tumoral effects of orexins and also their anti-inflammatory properties.
  • To define the structure-function relationships of orexins and OX1R in order to develop new agonists having a therapeutical interest in the treatment of digestive cancers (colon, pancreas and liver). Indeed, the determination of residues involving in the interaction between orexins and OX1R using alanine-scanning, side directed mutagenesis associated to 3D molecular modeling approaches will allow us to design, in collaboration with pharmaceutical industry, new molecules. Moreover, alternative strategies such as the production of antibodies mimicking the agonist properties of orexins will be planned Anti-tumoral effect of orexins in xenografted colon cancer cell line (HT-29)

This project could lead :

  1. To decipher the role of a number of GPCRs including OX receptor in the induction of apoptosis processes;
  2. To define the potential role of orexins in the treatment of digestive cancers and IBD;
  3. To design innovative molecules having therapeutical interest.

3D model of OX1R

 

Landmark publications

  • Publication date : 13 January 2020 More

    The histone acetyltransferase hMOF promotes vascular invasion in hepatocellular carcinoma Liver Int. 2020 Jan 13

    Autors : Poté Nicolas Cros Jérome Laouirem Samira Raffenne Jérome Negrão M ALBUQUERQUE Miguel Bedossa Pierre Godinho Ferreira M Ait Si Ali S Fior R Paradis Valérie

  • Publication date : 31 December 2019 More

    Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma Liver Int. 2019 Dec;39

    Autors : Gigante E Ronot Maxime Bertin C Ciolina M Bouattour M Dondero F Cauchy F Soubrane Olivier Paradis Valérie

  • Publication date : 19 December 2019 More

    Metabolic syndrome and hepatic surgery J Visc Surg. 2019 Dec 19. pii: S1878-7886(19)30180-8. doi: 10.1016/j.jviscsurg.2019.11.004

    Autors : Hobeika C Ronot Maxime Beaufrere A Paradis Valérie Soubrane Olivier Cauchy F

  • Publication date : 18 November 2019 More

    hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status Cancers (Basel).

    Autors : Raffenne Jérome Nicolle R Puleo F Le Corre D Boyez C Marechal R Emile JF Demetter P Bardier A Laurent-Puig P De Mestier Louis Paradis Valérie Couvelard Anne VanLathem JL MacKey JR Bachet JB Svrcek M Cros Jérome

  • Publication date : 01 April 2019 More

    Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome. Oncogene. 2019 Apr;38(16):3033-3046

    Autors : Laouirem Samira Sannier A Norkowski E Cauchy F Doblas Sabrina Rautou Pierre-Emmanuel ALBUQUERQUE Miguel Garteiser Philippe Sognigbé L Raffenne Jérome Van Beers Bernard Soubrane Olivier Bedossa Pierre Cros Jérome Paradis Valérie

  • Publication date : 01 January 2019 More

    Proteomic Landscape of Cholangiocarcinomas Reveals Three Different Subgroups According to Their Localization and the Aspect of Non-Tumor Liver. Proteomics Clin Appl. 2019 Jan;13(1):e1800128

    Autors : Le Faouder Julie Gigante E Léger T ALBUQUERQUE Miguel Beaufrère A Soubrane Olivier Dokmak S Camadro JM Cros Jérome Paradis Valérie

  • Publication date : 02 November 2018 More

    Obesity-induced pancreatopathy in rats is reversible after bariatric surgery Sci Rep

    Autors : Rebours Vinciane Garteiser Philippe Ribeiro-Parenti Lara Cavin JB Doblas Sabrina Page Gwenael Bado André Couvineau Alain Ruszniewski Philippe Paradis Valérie Le Gall Maude Van Beers Bernard Couvelard Anne

  • Publication date : 18 August 2018 More

    Ectopic expression of OX1R in ulcerative colitis mediates anti-inflammatory effect of orexin-A. Biochim Biophys Acta Mol Basis Dis. 2018 Nov;1864(11):3618-3628

    Autors : Messal N Fernandez N Dayot Stephanie Gratio Valérie Nicole Pascal Prochasson C Chantret Isabelle LeGuilloux G Jarry A Couvelard Anne Treton Xavier Voisin Thierry Ogier-Denis Eric Couvineau Alain

  • Publication date : 09 January 2018 More

    In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. Oncotarget. 2018 Jan 9;9(6):6952-6967

    Autors : Dayot Stephanie Speisky D Couvelard Anne Bourgoin P Gratio Valérie Cros Jérome Rebours Vinciane Sauvanet Alain Bedossa Pierre Paradis Valérie Ruszniewski Philippe Couvineau Alain Voisin Thierry

 
 

Newsletter du site Web

Ajout des contacts utiles sur la colonne de gauche (intranet)

Actuality


The latest notable publications

  • Publication date : 01 July 2021 More

    Acute-on-chronic liver failure: A distinct clinical syndrome J Hepatol .

    Autors : Moreau Richard Bin Gao Maria Papp Rafael Bañares Patrick S Kamath

  • Publication date : 02 June 2021 More

    Role of extracellular vesicles in liver diseases and their therapeutic potential Adv Drug Deliv Rev .

    Autors : Enis Kostallari Shantha Valainathan Biquard Louise Vijay H Shah Rautou Pierre-Emmanuel

  • Publication date : 11 March 2021 More

    Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features Cancers (Basel) .

    Autors : Raffenne Jérome Fernando A Martin Rémy Nicolle Marina Konta Yuna Blum Jérôme Torrisani Francesco Puleo Jean Baptiste Bachet Magali Svrcek Armel Bardier-Dupas Jean Francois Emile Peter Demetter Miroslav Radman Jean Luc Van Laethem Hammel Pascal Rebours Vinciane Paradis Valérie Couvelard Anne Cros Jérome